NASDAQ:GNCA Genocea Biosciences (GNCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Genocea Biosciences Stock (NASDAQ:GNCA) 30 days 90 days 365 days Advanced Chart Get Genocea Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume83,499 shsMarket Capitalization$6,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.Read More… Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GNCA Stock News HeadlinesGenocea Biosciences (NASDAQ:GNCA) Now Covered by Analysts at StockNews.comApril 19 at 2:49 AM | americanbankingnews.comStockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)April 13, 2025 | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 19, 2025 | Paradigm Press (Ad)Genocea Biosciences Inc GNCAQJanuary 5, 2024 | morningstar.comGNCAQ Genocea Biosciences, Inc.January 27, 2023 | seekingalpha.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 31, 2022 | thestreet.comGenocea Biosciences, Inc. (GNCA)August 9, 2022 | uk.finance.yahoo.comGRPN, GNCA and LAB among mid-day moversMay 27, 2022 | seekingalpha.comSee More Headlines GNCA Stock Analysis - Frequently Asked Questions How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) issued its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter. How do I buy shares of Genocea Biosciences? Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW) and Micron Technology (MU). Company Calendar Last Earnings10/27/2021Today4/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNCA CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,200,000.00 Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.91 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / BookN/AMiscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$6,000.00 OptionableNot Optionable Beta1.61 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:GNCA) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.